Estonia - Estonia - Ecolab

ecolab deutschland gmbh -

Kesatuan Eropah - Estonia - EMA (European Medicines Agency)

recordati rare diseases - veevaba betaiini - homotsüstiinuria - muud alimentary seedetrakti ja ainevahetust tooted, - adjunctive treatment of homocystinuria, involving deficiencies or defects in:cystathionine beta-synthase (cbs);5,10-methylene-tetrahydrofolate reductase (mthfr);cobalamin cofactor metabolism (cbl). cystadane should be used as supplement to other therapies such as vitamin b6 (pyridoxine), vitamin b12 (cobalamin), folate and a specific diet.

Kesatuan Eropah - Estonia - EMA (European Medicines Agency)

bayer ag - rivaroksabaan - arthroplasty, replacement; venous thromboembolism - antitrombootilised ained - xarelto, co-manustada atsetüülsalitsüülhape (asa) üksi või koos asa pluss clopidogrel või ticlopidine, on näidustatud ennetamine atherothrombotic sündmuste täiskasvanud patsientidel pärast äge koronaarsündroom (acs) kõrgenenud südame biomarkerite. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. täiskasvanud patsientidel, kellele tehti plaaniline puusa- või põlveliigese asendamise operatsiooni venoosse trombemboolia (vte) ennetamine. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Estonia - Estonia - Ravimiamet

medochemie limited - pregabaliin - kõvakapsel - 75mg 14tk; 75mg 112tk; 75mg 100tk; 75mg 30tk; 75mg 56tk; 75mg 84tk; 75mg 21tk

Estonia - Estonia - Ravimiamet

medochemie limited - linesoliid - õhukese polümeerikattega tablett - 600mg 100tk; 600mg 20tk; 600mg 14tk; 600mg 10tk; 600mg 24tk; 600mg 60tk; 600mg 50tk; 600mg 30tk

Estonia - Estonia - Ravimiamet

medochemie limited - vildagliptiin - tablett - 50mg 112tk; 50mg 180tk; 50mg 56tk; 50mg 28tk; 50mg 30tk; 50mg 90tk; 50mg 60tk; 50mg 14tk; 50mg 336tk

Estonia - Estonia - Ravimiamet

medochemie limited - venlafaksiin - toimeainet prolongeeritult vabastav kõvakapsel - 150mg 100tk; 150mg 20tk; 150mg 30tk; 150mg 28tk; 150mg 50tk

Estonia - Estonia - Ravimiamet

medochemie limited - duloksetiin - gastroresistentne kõvakapsel - 30mg 30tk; 30mg 140tk; 30mg 100tk; 30mg 28tk; 30mg 196tk; 30mg 56tk; 30mg 98tk; 30mg 84tk

Estonia - Estonia - Ravimiamet

medochemie limited - lorasepaam - tablett - 1mg 20tk; 1mg 60tk; 1mg 100tk; 1mg 10tk; 1mg 14tk; 1mg 500tk; 1mg 28tk; 1mg 50tk; 1mg 15tk; 1mg 90tk

Estonia - Estonia - Ravimiamet

medochemie limited - risperidoon - õhukese polümeerikattega tablett - 1mg 30tk; 1mg 10tk; 1mg 90tk; 1mg 120tk; 1mg 100tk